**SECTION A: IIH/PTCS CLINICAL TREATMENT STUDIES WITH CA-INHIBITORS\
**

STUDY_ID,PARENT_TRIAL_ID,FIRST_AUTHOR,YEAR,JOURNAL,FULL_CITATION_TEXT,DOI,COUNTRY_OR_REGION,MULTICENTER,N_CENTERS,STUDY_DESIGN_MAIN,STUDY_DESIGN_DETAIL,RANDOMIZATION_RATIO,BLINDING,DIAGNOSIS_LABEL_AS_REPORTED,DIAGNOSIS_CRITERIA_NAME,KEY_INCLUSION_CRITERIA_TEXT,KEY_EXCLUSION_CRITERIA_TEXT,BASELINE_VISUAL_SEVERITY_CATEGORY_AS_REPORTED,N_RANDOMIZED_TOTAL,N_ANALYZED_PRIMARY_OUTCOME_TOTAL,PRIMARY_ENDPOINT_NAME,PRIMARY_ENDPOINT_TYPE,PRIMARY_ENDPOINT_MAIN_TIMEPOINT_AS_REPORTED,MAX_FOLLOWUP_DURATION_AS_REPORTED,TRIAL_REGISTRATION_ID,FUNDING_SOURCE_TYPE,FUNDING_SOURCE_TEXT,NOTES_INTERNAL_VALIDITY,PDF_SOURCE_IDENTIFIER

Wall_2014_JAMA,IIHTT,Wall,2014,JAMA,\"Wall M, McDermott MP, Kieburtz KD,
et al. Effect of acetazolamide on visual function in patients with
idiopathic intracranial hypertension and mild visual loss: the
Idiopathic Intracranial Hypertension Treatment Trial. JAMA.
2014;311(16):1641-1651.\",10.1001/jama.2014.3312,USA;Canada,Yes,38,Randomized_Trial,Double-blind,
placebo-controlled, randomized trial,1:1,DoubleBlind,Idiopathic
intracranial hypertension,Modified Dandy criteria,Age 18-60 years with
IIH and mild visual loss (PMD -2 to -7 dB) and papilledema.,Prior IIH
surgery; contraindication to acetazolamide; pregnancy; severe visual
loss.,mild visual loss,165,165,Change in perimetric mean deviation (PMD)
from baseline,Continuous,6 months,6
months,NCT01003639,Government,National Eye Institute of the National
Institutes ofHealth (NIH),Intention-to-treat analysis; prespecified
analyses.,wall2014.pdf

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,Celebisoy,2007,Acta
Neurol Scand,\"Celebisoy N, Gökçay F, Şirin H, Akyürekli Ö. Treatment of
idiopathic intracranial hypertension: topiramate vs acetazolamide, an
open-label study. Acta Neurol Scand.
2007;116(5):322-327.\",10.1111/j.1600-0404.2007.00905.x,Turkey,No,1,Prospective_Cohort,Open-label
prospective study with alternating assignment,NA,OpenLabel,Idiopathic
intracranial hypertension (IIH),IHS classification of headache disorders
second edition,Patients diagnosed as IIH.,Patient dropped out due to
rapid visual deterioration.,NR,41,40,Improvement in the visual
fields,Ordinal,3, 6 and 12 months,12 months,NR,NR,NR,Patients were
randomly assigned by alternating choice of drugs; 1 patient dropped
out.,10.1111@j.1600-0404.2007.00905.x.pdf

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,Johnson,1998,Ophthalmology,\"Johnson
LN, Krohel GB, Madsen RW, March GA Jr. The role of weight loss and
acetazolamide in the treatment of idiopathic intracranial hypertension
(pseudotumor cerebri). Ophthalmology.
1998;105(12):2313-2317.\",10.1016/s0161-6420(98)91234-9,USA,NR,NR,Retrospective_Cohort,Retrospective
cohort study,NA,NR,Idiopathic intracranial hypertension (pseudotumor
cerebri),Modified Dandy criteria,Diagnosis of IIH and availability of
follow-up data.,NR,Visual acuity 20/20 or better (in 86% of
eyes),57,57,Change in papilledema grade,Ordinal,NR,NR (mean follow-up
1.8 years),NR,NR,NR,Retrospective; treatment not randomized; analysis
based on observed weight change and treatment.,johnson1998.pdf

Johnson_2013_Neurology,JOHNSON_WEIGHTLOSS_IIH,Johnson,2013,Neurology,\"Johnson
LN, Biousse V, Bruce BB, et al. The role of weight loss and
acetazolamide in the treatment of idiopathic intracranial hypertension.
Neurology.
2013;81(13):e97-e98.\",10.1212/WNL.0b013e3182a55f2f,USA,NA,NA,Other,Letter
to the Editor,NA,NA,Idiopathic intracranial
hypertension,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,NR,NR,This is a letter
commenting on the IIHTT and referencing the Johnson 1998
paper.,NEUROLOGY2013541045.pdf

Keltner_2014_IOVS,IIHTT,Keltner,2014,Invest Ophthalmol Vis Sci,\"Keltner
JL, Johnson CA, Cello KE, Wall M; NORDIC Idiopathic Intracranial
Hypertension Study Group. Baseline visual field findings in the
Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Invest
Ophthalmol Vis Sci.
2014;55(5):3200-3207.\",10.1167/iovs.14-14289,USA;Canada,Yes,38,Randomized_Trial,Baseline
characteristics from a randomized trial,NA,MaskOutcomeOnly,Idiopathic
intracranial hypertension (IIH),Modified Dandy criteria,Enrolled in the
IIHTT (Age 18-60, mild visual loss, papilledema).,NA (baseline
paper),mild visual loss,165,NA,NA (baseline paper),NA,NA,6
months,NCT01003639,Government,National Eye Institute (NEI),This paper
reports baseline data only.,i1552-5783-55-5-3200.pdf

Kupersmith_2016_IOVS,IIHTT,Kupersmith,2016,Invest Ophthalmol Vis
Sci,\"Kupersmith MJ, Cello K, Keltner J, et al. Acetazolamide effect on
cerebrospinal fluid biomarkers in the Idiopathic Intracranial
Hypertension Treatment Trial. Invest Ophthalmol Vis Sci.
2016;57(3):805-811.\",10.1167/iovs.15-18231,USA;Canada,Yes,NR,Randomized_Trial,Substudy
of a randomized trial,1:1,DoubleBlind,Idiopathic intracranial
hypertension (IIH),Modified Dandy criteria,Subset of IIHTT participants
with CSF samples at baseline and 6 months.,NA (substudy),mild visual
loss,165,57,Change in CSF biomarkers,Continuous,6 months,6
months,NCT01003639,Government,National Eye Institute (NEI),Analysis of a
subset of the IIHTT cohort (n=57).,i1552-5783-57-3-805.pdf

Wong_2007_BMCOphthalmol,WONG_WEIGHTLOSS_IIH,Wong,2007,BMC
Ophthalmology,\"Wong R, Madill SA, Pandey P, Riordan-Eva P. Idiopathic
intracranial hypertension: the association between weight loss and the
requirement for systemic treatment. BMC Ophthalmology.
2007;7:15.\",10.1186/1471-2415-7-15,UK,No,1,Retrospective_Cohort,Retrospective
review,NA,NR,Idiopathic intracranial hypertension (IIH),Standard
diagnostic criteria \[12\],Diagnosis of IIH and regular review for at
least 12 months.,Pregnancy; surgical intervention that led to treatment
cessation.,NR,36,36,Discontinuation of systemic treatment,Dichotomous,24
months or more,Mean 30 months (range 12-89),NR,NR,NR,Retrospective;
analysis based on observed weight change at last
review.,1471-2415-7-15.pdf

Markey_2017_JMIR,IIHDT,Markey,2017,JMIR Res Protoc,\"Markey KA, Ottridge
R, Mitchell JL, et al. Assessing the Efficacy and Safety of an
11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the
Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical
Methods and Design for a Phase II Randomized Controlled Trial. JMIR Res
Protoc.
2017;6(9):e181.\",10.2196/resprot.7690,UK,Yes,NR,Randomized_Trial,Phase
II, double-blind, randomized, placebo-controlled trial
protocol,1:1,DoubleBlind,Idiopathic Intracranial Hypertension
(IIH),Modified Dandy criteria,Age 18-55, active IIH (LP \> 25 cmH2O),
papilledema.,Prior IIH surgery; contraindication to AZD4017; pregnancy;
diabetes.,Active IIH (papilledema),30,30,Change in ICP from
baseline,Continuous,12 weeks,24 weeks,NCT02124486,Mixed,NIHR; Medical
Research Council UK,This is a protocol paper; results are not
included.,Markey_2017_JMIR.pdf

Markey_2020_BrainCommun,IIHDT,Markey,2020,Brain Communications,\"Markey
K, Mitchell J, Botfield H, et al. 11β-Hydroxysteroid dehydrogenase type
1 inhibition in idiopathic intracranial hypertension: a double-blind
randomized controlled trial. Brain Commun.
2020;2(1):fcz050.\",10.1093/braincomms/fcz050,UK,Yes,6,Randomized_Trial,Phase
II, double-blind, randomized, placebo-controlled
trial,1:1,DoubleBlind,Idiopathic intracranial hypertension
(IIH),Modified Dandy criteria,Age 18-55, active IIH (LP \> 25 cmH2O),
papilledema.,Prior IIH surgery; contraindication to AZD4017; pregnancy;
diabetes.,Active IIH (papilledema),31,31,Change in ICP from baseline (at
12 weeks),Continuous,12 weeks,24 weeks,NCT02124486,Mixed,NIHR; Medical
Research Council UK; Wellcome Trust,ITT analysis.,fcz050.pdf

Cello_2016_JNeuroophthalmol,IIHTT,Cello,2016,J Neuroophthalmol,\"Cello
KE, Keltner JL, Johnson CA, et al. Visual field outcomes for the
Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). J
Neuroophthalmol.
2016;36(1):16-24.\",10.1097/WNO.0000000000000331,USA;Canada,Yes,38,Randomized_Trial,Secondary
analysis of a randomized trial,NA,DoubleBlind,Idiopathic intracranial
hypertension (IIH),Modified Dandy criteria,Enrolled in the IIHTT (Age
18-60, mild visual loss, papilledema).,NA (secondary analysis),mild
visual loss,165,165,Visual field outcomes (PMD
improvement/worsening),Dichotomous,6 months,6
months,NCT01003639,Government,National Eye Institute (NEI),Secondary
analysis of IIHTT data.,cello2016.pdf

Code snippet

STUDY_ID,PARENT_TRIAL_ID,ARM_ID,ARM_LABEL_AS_REPORTED,IS_PRIMARY_CA_INHIBITOR_ARM,PRIMARY_DRUG_NAME,PRIMARY_DRUG_MECHANISM_TEXT,CAI_DRUG_NAME,CAI_ROUTE,CAI_FORMULATION,CAI_STARTING_DOSE_MG_PER_DAY,CAI_TARGET_DOSE_MG_PER_DAY_LOW,CAI_TARGET_DOSE_MG_PER_DAY_HIGH,CAI_MAX_ALLOWED_DOSE_MG_PER_DAY,CAI_TITRATION_SCHEDULE_TEXT,CAI_DOSE_ADJUSTMENT_RULES_TEXT,CAI_MEAN_ACTUAL_DAILY_DOSE_MG_PER_DAY,CAI_MEDIAN_ACTUAL_DAILY_DOSE_MG_PER_DAY,CAI_MEAN_DOSE_MG_PER_KG_PER_DAY,CAI_TREATMENT_DURATION_MEAN_DAYS,CAI_TREATMENT_DURATION_MEDIAN_DAYS,CAI_TREATMENT_DURATION_RANGE_DAYS,CAI_TREATMENT_STEADY_STATE_OR_FIXED_TEXT,BACKGROUND_CAI_ALLOWED,BACKGROUND_CAI_DETAILS_TEXT,WEIGHT_LOSS_PROGRAM_INCLUDED,WEIGHT_LOSS_PROGRAM_DETAILS,OTHER_CO_INTERVENTIONS_TEXT,SURGICAL_RESCUE_ALLOWED,SURGICAL_RESCUE_TYPES_TEXT,N_RANDOMIZED_ARM,N_ANALYZED_PRIMARY_OUTCOME_ARM,N_WITHDRAWN_TOTAL,N_WITHDRAWN_DUE_TO_AE,N_LOST_TO_FOLLOWUP,N_CROSSOVER_TO_OTHER_ARM,ARM_NOTES

Wall_2014_JAMA,IIHTT,ACZ,Acetazolamide,Yes,Acetazolamide,carbonic
anhydrase inhibitor,Acetazolamide,Oral,NR,1000,NR,4000,4000,\"Increased
by 250 mg every 6 days, up to 16 tablets (4 g) daily\",Titrated to
maximum tolerated dose up to 4g/day,2506,NR,NR,NR,NR,NR,Titrated to max
tolerated,NA,NA,Yes,low-sodium weight-reduction diet,\"All participants
received dietary advice\",Yes,NR,86,86,NR,NR,NR,NR,NR

Wall_2014_JAMA,IIHTT,Placebo,Placebo,No,Placebo,placebo,None,Oral,NR,NA,NA,NA,NA,\"Increased
by 1 tablet every 6 days, up to 16 tablets daily\",Titrated to maximum
tolerated dose up to 16 tablets/day,NA,NA,NA,NR,NR,NR,Titrated to max
tolerated,NA,NA,Yes,low-sodium weight-reduction diet,\"All participants
received dietary advice\",Yes,NR,79,79,NR,NR,NR,NR,NR

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ACZ,Acetazolamide,Yes,Acetazolamide,carbonic
anhydrase inhibitor,Acetazolamide,Oral,NR,500,1000,1500,1500,Started at
500 mg/day,Titrated to efficacious dose (1000-1500 mg
daily),NR,NR,NR,NR,NR,NR,Titrated to efficacious
dose,NA,NA,NR,NR,NR,NR,NR,20,20,NR,0,NR,NR,NR

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,Topiramate,Topiramate,Yes,Topiramate,carbonic
anhydrase inhibitor,Topiramate,Oral,NR,50,100,150,150,Started at 50
mg/day,Gradually titrated to efficacious dose (100-150 mg
daily),NR,NR,NR,NR,NR,NR,Titrated to efficacious
dose,NA,NA,NR,NR,NR,NR,NR,20,20,0,0,NR,NR,1 patient dropped out early
due to visual deterioration and had shunt.

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,WeightLoss_plus_ACZ,Weight
loss plus acetazolamide,Yes,Acetazolamide,carbonic anhydrase
inhibitor,Acetazolamide,Oral,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,NA,NA,Yes,Weight
loss,NR,Yes,NR,NR,28,NR,NR,NR,NR,Observational group

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,WeightLoss_Only,Weight
loss only,No,None,lifestyle weight-loss
program,None,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,NR,NR,NR,NA,NA,Yes,Weight
loss,NR,Yes,NR,NR,9,NR,NR,NR,NR,Observational group

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,ACZ_Only,Acetazolamide
only,Yes,Acetazolamide,carbonic anhydrase
inhibitor,Acetazolamide,Oral,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,NR,NA,NA,No,No
weight loss,NR,Yes,NR,NR,16,NR,NR,NR,NR,Observational group

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,NoTreatment,No
treatment,No,None,No
treatment,None,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,NR,NR,NR,NA,NA,No,No
weight loss,NR,Yes,NR,NR,4,NR,NR,NR,NR,Observational group

Johnson_2013_Neurology,JOHNSON_WEIGHTLOSS_IIH,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Letter
to editor, no arms.

Keltner_2014_IOVS,IIHTT,AllArmsCombined,Baseline data from all 165 IIHTT
participants,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,NA,NA,165,NA,NA,NA,NA,NA,Baseline
paper, data pooled.

Kupersmith_2016_IOVS,IIHTT,ACZ,Acetazolamide,Yes,Acetazolamide,carbonic
anhydrase inhibitor,Acetazolamide,Oral,NR,1000,NR,4000,4000,Titrated to
max 4 g/day,NR,NR,NR,NR,NR,NR,NR,Titrated to max
tolerated,NA,NA,Yes,low-sodium weight-reduction
diet,NR,Yes,NR,NR,29,NR,NR,NR,NR,Substudy cohort from IIHTT

Kupersmith_2016_IOVS,IIHTT,Placebo,Placebo,No,Placebo,placebo,None,Oral,NR,NA,NA,NA,NA,Titrated
to max 16 tablets/day,NR,NA,NA,NA,NR,NR,NR,Titrated to max
tolerated,NA,NA,Yes,low-sodium weight-reduction
diet,NR,Yes,NR,NR,28,NR,NR,NR,NR,Substudy cohort from IIHTT

Wong_2007_BMCOphthalmol,WONG_WEIGHTLOSS_IIH,WeightGain,BMI
increase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,NR,NR,NR,NA,NA,Yes,Weight
loss recommended,NR,Yes,Lumbo-peritoneal shunt; Optic nerve sheath
fenestration,NR,17,NR,NR,NR,NR,Observational group defined by weight
change at last follow-up (\>=12mo).

Wong_2007_BMCOphthalmol,WONG_WEIGHTLOSS_IIH,WeightLoss,BMI
decrease,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,NR,NR,NR,NA,NA,Yes,Weight
loss recommended,NR,Yes,Lumbo-peritoneal shunt; Optic nerve sheath
fenestration,NR,19,NR,NR,NR,NR,Observational group defined by weight
change at last follow-up (\>=12mo).

Markey_2017_JMIR,IIHDT,AZD4017,AZD4017,No,AZD4017,11β-HSD1
inhibitor,None,Oral,NR,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,NR,NR,Fixed
dose,No,NA,Yes,Community-based weight management programme (Weight
Watchers),NR,Yes,CSF diversion; ONSF; VSS,15,15,NR,NR,NR,NR,Protocol
paper

Markey_2017_JMIR,IIHDT,Placebo,Placebo,No,Placebo,placebo,None,Oral,NR,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,NR,NR,Fixed
dose,No,NA,Yes,Community-based weight management programme (Weight
Watchers),NR,Yes,CSF diversion; ONSF; VSS,15,15,NR,NR,NR,NR,Protocol
paper

Markey_2020_BrainCommun,IIHDT,AZD4017,AZD4017,No,AZD4017,11β-HSD1
inhibitor,None,Oral,NR,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,NR,NR,Fixed dose
(400 mg twice daily),No,NA,Yes,Weight management
advice,NR,Yes,NR,16,16,2,2,NR,NR,NR

Markey_2020_BrainCommun,IIHDT,Placebo,Placebo,No,Placebo,placebo,None,Oral,NR,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,NR,NR,Fixed
dose,No,NA,Yes,Weight management advice,NR,Yes,NR,15,15,1,0,NR,NR,NR

Cello_2016_JNeuroophthalmol,IIHTT,ACZ,Acetazolamide,Yes,Acetazolamide,carbonic
anhydrase inhibitor,Acetazolamide,Oral,NR,1000,NR,4000,4000,Titrated to
max 4 g/day,NR,NR,NR,NR,NR,NR,NR,Titrated to max
tolerated,NA,NA,Yes,low-sodium weight-reduction
diet,NR,Yes,NR,86,86,NR,NR,NR,NR,Secondary analysis of IIHTT

Cello_2016_JNeuroophthalmol,IIHTT,Placebo,Placebo,No,Placebo,placebo,None,Oral,NR,NA,NA,NA,NA,Titrated
to max 16 tablets/day,NR,NA,NA,NA,NR,NR,NR,Titrated to max
tolerated,NA,NA,Yes,low-sodium weight-reduction
diet,NR,Yes,NR,79,79,NR,NR,NR,NR,Secondary analysis of IIHTT

Code snippet

STUDY_ID,PARENT_TRIAL_ID,ARM_ID,VARIABLE_DOMAIN,VARIABLE_NAME_STANDARDIZED,VARIABLE_NAME_AS_REPORTED,VARIABLE_DEFINITION_TEXT,N_BASELINE,CENTRAL_TENDENCY_TYPE,CENTRAL_VALUE,SPREAD_TYPE,SPREAD_VALUE_1,SPREAD_VALUE_2,EVENT_COUNT,TOTAL_COUNT,UNITS_OR_SCALE,BASELINE_SOURCE_LOCATION

Wall_2014_JAMA,IIHTT,ACZ,Demographics,Age,Age
(y),NR,86,Mean,29,SD,7.5,NA,NA,NA,years,Table 1

Wall_2014_JAMA,IIHTT,Placebo,Demographics,Age,Age
(y),NR,79,Mean,29.2,SD,8.6,NA,NA,NA,years,Table 1

Wall_2014_JAMA,IIHTT,ACZ,Demographics,Sex_Female_Percent,Female sex
(%),NR,86,Proportion,97.7,None,NR,NA,84,86,%,Table 1

Wall_2014_JAMA,IIHTT,Placebo,Demographics,Sex_Female_Percent,Female sex
(%),NR,79,Proportion,100,None,NR,NA,79,79,%,Table 1

Wall_2014_JAMA,IIHTT,ACZ,Demographics,Race_Black_Percent,Black race
(%),NR,86,Proportion,26.7,None,NR,NA,23,86,%,Table 1

Wall_2014_JAMA,IIHTT,Placebo,Demographics,Race_Black_Percent,Black race
(%),NR,79,Proportion,26.6,None,NR,NA,21,79,%,Table 1

Wall_2014_JAMA,IIHTT,ACZ,Anthropometrics,Weight,Weight
(kg),NR,86,Mean,103.7,SD,21.8,NA,NA,NA,kg,Table 1

Wall_2014_JAMA,IIHTT,Placebo,Anthropometrics,Weight,Weight
(kg),NR,79,Mean,101.9,SD,20.4,NA,NA,NA,kg,Table 1

Wall_2014_JAMA,IIHTT,ACZ,Anthropometrics,BMI,Body mass
index,NR,86,Mean,39.9,SD,8.4,NA,NA,NA,kg/m\^2,Table 1

Wall_2014_JAMA,IIHTT,Placebo,Anthropometrics,BMI,Body mass
index,NR,79,Mean,40,SD,8.3,NA,NA,NA,kg/m\^2,Table 1

Wall_2014_JAMA,IIHTT,ACZ,ICP_CSF,CSF_OpeningPressure,CSF opening
pressure (cm H2O),Measured in lateral decubitus
position,86,Mean,34.3,SD,8.2,NA,NA,NA,cmH2O,Table 1

Wall_2014_JAMA,IIHTT,Placebo,ICP_CSF,CSF_OpeningPressure,CSF opening
pressure (cm H2O),Measured in lateral decubitus
position,79,Mean,35.1,SD,9.6,NA,NA,NA,cmH2O,Table 1

Wall_2014_JAMA,IIHTT,ACZ,Visual_Function,VisualField_PMD,Perimetric mean
deviation (dB) (study eye),Study eye = eye with worse
PMD,86,Mean,-3.53,SD,1.49,NA,NA,NA,dB,Table 1

Wall_2014_JAMA,IIHTT,Placebo,Visual_Function,VisualField_PMD,Perimetric
mean deviation (dB) (study eye),Study eye = eye with worse
PMD,79,Mean,-3.45,SD,1.52,NA,NA,NA,dB,Table 1

Wall_2014_JAMA,IIHTT,ACZ,Visual_Function,Papilledema_FrisenGrade,Papilledema
grade (Frisen scale) (study
eye),NR,86,Mean,2.8,SD,1,NA,NA,NA,score,Table 1

Wall_2014_JAMA,IIHTT,Placebo,Visual_Function,Papilledema_FrisenGrade,Papilledema
grade (Frisen scale) (study
eye),NR,79,Mean,2.8,SD,1.1,NA,NA,NA,score,Table 1

Wall_2014_JAMA,IIHTT,ACZ,Clinical_Severity,Headache_Disability_HIT6,Headache
Impact Test (HIT-6) score,NR,86,Mean,60.2,SD,7.1,NA,NA,NA,score,Table 1

Wall_2014_JAMA,IIHTT,Placebo,Clinical_Severity,Headache_Disability_HIT6,Headache
Impact Test (HIT-6) score,NR,79,Mean,60.8,SD,7.1,NA,NA,NA,score,Table 1

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ACZ,Demographics,Age,Age
(median),NR,20,Median,35,Range,16,49,NA,NA,years,Table 1

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,Topiramate,Demographics,Age,Age
(median),NR,20,Median,32,Range,16,51,NA,NA,years,Table 1

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ACZ,Demographics,Sex_Female_Percent,Sex
(M/F),NR,20,Proportion,85,None,NR,NA,17,20,%,Table 1

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,Topiramate,Demographics,Sex_Female_Percent,Sex
(M/F),NR,20,Proportion,90,None,NR,NA,18,20,%,Table 1

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ACZ,Anthropometrics,Weight,Weight
(kg) (median),NR,20,Median,70,Range,63,95,NA,NA,kg,Table 1

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,Topiramate,Anthropometrics,Weight,Weight
(kg) (median),NR,20,Median,73.5,Range,60,95,NA,NA,kg,Table 1

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ACZ,ICP_CSF,CSF_OpeningPressure,CSF
pressure (mmH2O)
(median),NR,20,Median,300,Range,225,700,NA,NA,mmH2O,Table 1

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,Topiramate,ICP_CSF,CSF_OpeningPressure,CSF
pressure (mmH2O)
(median),NR,20,Median,342.5,Range,250,850,NA,NA,mmH2O,Table 1

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ACZ,Visual_Function,Papilledema_FrisenGrade,Papilledema
grades at the initial visit - Grade 3,Frisen\'s
scheme,20,CountOnly,3,None,NR,NA,3,20,count,Table 2

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ACZ,Visual_Function,Papilledema_FrisenGrade,Papilledema
grades at the initial visit - Grade 4,Frisen\'s
scheme,20,CountOnly,14,None,NR,NA,14,20,count,Table 2

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ACZ,Visual_Function,Papilledema_FrisenGrade,Papilledema
grades at the initial visit - Grade 5,Frisen\'s
scheme,20,CountOnly,3,None,NR,NA,3,20,count,Table 2

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,Topiramate,Visual_Function,Papilledema_FrisenGrade,Papilledema
grades at the initial visit - Grade 3,Frisen\'s
scheme,20,CountOnly,2,None,NR,NA,2,20,count,Table 2

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,Topiramate,Visual_Function,Papilledema_FrisenGrade,Papilledema
grades at the initial visit - Grade 4,Frisen\'s
scheme,20,CountOnly,5,None,NR,NA,5,20,count,Table 2

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,Topiramate,Visual_Function,Papilledema_FrisenGrade,Papilledema
grades at the initial visit - Grade 5,Frisen\'s
scheme,20,CountOnly,13,None,NR,NA,13,20,count,Table 2

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ACZ,Visual_Function,VisualField_Grade,Visual
field grades at the initial visit - Grade 1,Criteria of Wall and
George,20,CountOnly,1,None,NR,NA,1,20,count,Table 2

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ACZ,Visual_Function,VisualField_Grade,Visual
field grades at the initial visit - Grade 2,Criteria of Wall and
George,20,CountOnly,5,None,NR,NA,5,20,count,Table 2

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ACZ,Visual_Function,VisualField_Grade,Visual
field grades at the initial visit - Grade 3,Criteria of Wall and
George,20,CountOnly,14,None,NR,NA,14,20,count,Table 2

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,Topiramate,Visual_Function,VisualField_Grade,Visual
field grades at the initial visit - Grade 2,Criteria of Wall and
George,20,CountOnly,7,None,NR,NA,7,20,count,Table 2

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,Topiramate,Visual_Function,VisualField_Grade,Visual
field grades at the initial visit - Grade 3,Criteria of Wall and
George,20,CountOnly,13,None,NR,NA,13,20,count,Table 2

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,AllArmsCombined,Demographics,Age,Age
(yr),NR,57,Mean,32.2,SD,9.9,NA,NA,NA,years,Table 1

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,AllArmsCombined,Demographics,Sex_Female_Percent,Female
sex,NR,57,Proportion,98,None,NR,NA,56,57,%,Table 1

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,AllArmsCombined,Anthropometrics,Weight,Weight
(kg),NR,57,Mean,99.1,SD,21,NA,NA,NA,kg,Table 1

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,AllArmsCombined,Anthropometrics,BMI,Body
mass index (kg/m2),NR,57,Mean,35.8,SD,7.7,NA,NA,NA,kg/m\^2,Table 1

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,AllArmsCombined,ICP_CSF,CSF_OpeningPressure,Opening
CSF pressure (mm H2O),NR,57,Mean,345,SD,91,NA,NA,NA,mmH2O,Table 1

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,AllArmsCombined,Visual_Function,VisualAcuity_BetterThan_20_25_Percent,Initial
visual acuity \>= 20/25,NR,114,Proportion,86,None,NR,NA,98,114,%,Table 1

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,AllArmsCombined,Visual_Function,Papilledema_FrisenGrade,Initial
papilledema grade,Modified Frisén
scale,57,Mean,3,SD,1.1,NA,NA,NA,score,Table 1

Keltner_2014_IOVS,IIHTT,AllArmsCombined,Demographics,Age,Age
(y),NR,165,Mean,29.1,SD,8,NA,NA,NA,years,Table 1

Keltner_2014_IOVS,IIHTT,AllArmsCombined,Demographics,Sex_Female_Percent,Female,NR,165,Proportion,98.8,None,NR,NA,163,165,%,Table
1

Keltner_2014_IOVS,IIHTT,AllArmsCombined,Demographics,Race_Black_Percent,Black,NR,165,Proportion,26.7,None,NR,NA,44,165,%,Table
1

Keltner_2014_IOVS,IIHTT,AllArmsCombined,Demographics,Race_White_Percent,White,NR,165,Proportion,63.6,None,NR,NA,105,165,%,Table
1

Keltner_2014_IOVS,IIHTT,AllArmsCombined,Anthropometrics,BMI,Body Mass
Index,NR,165,Mean,39.9,SD,8.3,NA,NA,NA,kg/m\^2,Table 1

Keltner_2014_IOVS,IIHTT,AllArmsCombined,Clinical_Severity,SymptomDuration,Duration
of Symptoms (mo),NR,165,Median,3,IQR,1,7,NA,NA,months,Table 1

Keltner_2014_IOVS,IIHTT,AllArmsCombined,ICP_CSF,CSF_OpeningPressure,Opening
Pressure (cm H2O),NR,165,Mean,34.7,SD,8.9,NA,NA,NA,cmH2O,Table 1

Keltner_2014_IOVS,IIHTT,AllArmsCombined,Visual_Function,VisualField_PMD,PMD
(study eye),Perimetric Mean
Deviation,165,Mean,-3.5,SD,1.5,NA,NA,NA,dB,Table 2

Keltner_2014_IOVS,IIHTT,AllArmsCombined,Visual_Function,VisualField_PMD,PMD
(fellow eye),Perimetric Mean
Deviation,165,Mean,-2.1,SD,1.6,NA,NA,NA,dB,Table 2

Keltner_2014_IOVS,IIHTT,AllArmsCombined,Visual_Function,Papilledema_FrisenGrade,Frisen
Grade (study eye),NR,165,Mean,2.8,SD,1,NA,NA,NA,score,Table 2

Keltner_2014_IOVS,IIHTT,AllArmsCombined,Visual_Function,VisualAcuity_logMAR,Visual
Acuity (study eye),logMAR,165,Mean,0.01,SD,0.1,NA,NA,NA,logMAR,Table 2

Keltner_2014_IOVS,IIHTT,AllArmsCombined,Visual_Function,RNFL_Thickness_OCT,RNFL
Thickness (study eye),Spectral domain
OCT,165,Mean,173.8,SD,78.2,NA,NA,NA,μm,Table 2

Kupersmith_2016_IOVS,IIHTT,ACZ,Biochemistry,CSF_Leptin,CSF
Leptin,NR,29,Mean,125.1,SD,67.8,NA,NA,NA,ng/mL,Table 1

Kupersmith_2016_IOVS,IIHTT,Placebo,Biochemistry,CSF_Leptin,CSF
Leptin,NR,28,Mean,124.7,SD,69,NA,NA,NA,ng/mL,Table 1

Kupersmith_2016_IOVS,IIHTT,ACZ,Biochemistry,CSF_Cortisol,CSF
Cortisol,NR,29,Mean,2.3,SD,1.2,NA,NA,NA,μg/dL,Table 1

Kupersmith_2016_IOVS,IIHTT,Placebo,Biochemistry,CSF_Cortisol,CSF
Cortisol,NR,28,Mean,2.2,SD,0.9,NA,NA,NA,μg/dL,Table 1

Kupersmith_2016_IOVS,IIHTT,ACZ,Biochemistry,CSF_IL-2,CSF
IL-2,NR,29,Mean,0.9,SD,0.2,NA,NA,NA,pg/mL,Table 1

Kupersmith_2016_IOVS,IIHTT,Placebo,Biochemistry,CSF_IL-2,CSF
IL-2,NR,28,Mean,0.9,SD,0.3,NA,NA,NA,pg/mL,Table 1

Wong_2007_BMCOphthalmol,WONG_WEIGHTLOSS_IIH,AllArmsCombined,Demographics,Age,Age/years,NR,36,Mean,31.6,SD,10.1,NA,NA,NA,years,Text
p.3 & Table 2

Wong_2007_BMCOphthalmol,WONG_WEIGHTLOSS_IIH,AllArmsCombined,Demographics,Sex_Female_Percent,Sex,NR,36,Proportion,97.2,None,NR,NA,35,36,%,Text
p.3

Wong_2007_BMCOphthalmol,WONG_WEIGHTLOSS_IIH,AllArmsCombined,Anthropometrics,BMI,Body
mass index at
presentation/kg/m2,NR,35,Mean,36.6,SD,7.5,NA,NA,NA,kg/m\^2,Text p.3 &
Table 2

Wong_2007_BMCOphthalmol,WONG_WEIGHTLOSS_IIH,AllArmsCombined,ICP_CSF,CSF_OpeningPressure,Opening
pressure/cm H2O,NR,36,Mean,35.2,SD,10.9,NA,NA,NA,cmH2O,Table 2
(calculated)

Wong_2007_BMCOphthalmol,WONG_WEIGHTLOSS_IIH,AllArmsCombined,Clinical_Severity,FollowupDuration,Length
of follow up/months,NR,36,Mean,30,SD,16.3,NA,NA,NA,months,Text p.3

Markey_2020_BrainCommun,IIHDT,AZD4017,Demographics,Age,Age
(years),NR,16,Mean,32.2,SD,8.6,NA,NA,NA,years,Table 1

Markey_2020_BrainCommun,IIHDT,Placebo,Demographics,Age,Age
(years),NR,15,Mean,34.3,SD,9.9,NA,NA,NA,years,Table 1

Markey_2020_BrainCommun,IIHDT,AZD4017,Demographics,Sex_Female_Percent,Female
(n),NR,16,Proportion,100,None,NR,NA,16,16,%,Table 1

Markey_2020_BrainCommun,IIHDT,Placebo,Demographics,Sex_Female_Percent,Female
(n),NR,15,Proportion,100,None,NR,NA,15,15,%,Table 1

Markey_2020_BrainCommun,IIHDT,AZD4017,Anthropometrics,BMI,BMI
(kg/m2),NR,16,Mean,39.9,SD,6.5,NA,NA,NA,kg/m\^2,Table 1

Markey_2020_BrainCommun,IIHDT,Placebo,Anthropometrics,BMI,BMI
(kg/m2),NR,15,Mean,38.4,SD,5.6,NA,NA,NA,kg/m\^2,Table 1

Markey_2020_BrainCommun,IIHDT,AZD4017,ICP_CSF,CSF_OpeningPressure,ICP
(cmH2O),Lumbar puncture opening
pressure,16,Mean,34.3,SD,7.6,NA,NA,NA,cmH2O,Table 1

Markey_2020_BrainCommun,IIHDT,Placebo,ICP_CSF,CSF_OpeningPressure,ICP
(cmH2O),Lumbar puncture opening
pressure,15,Mean,34.4,SD,6.2,NA,NA,NA,cmH2O,Table 1

Markey_2020_BrainCommun,IIHDT,AZD4017,Visual_Function,VisualField_PMD,Perimetric
mean deviation (dB),Worse eye,16,Mean,-2,SD,1.2,NA,NA,NA,dB,Table 1

Markey_2020_BrainCommun,IIHDT,Placebo,Visual_Function,VisualField_PMD,Perimetric
mean deviation (dB),Worse eye,15,Mean,-2.1,SD,1.4,NA,NA,NA,dB,Table 1

Markey_2020_BrainCommun,IIHDT,AZD4017,Visual_Function,Papilledema_FrisenGrade,Papilloedema
grade (Frisén),NR,16,Mean,2.3,SD,0.9,NA,NA,NA,score,Table 1

Markey_2020_BrainCommun,IIHDT,Placebo,Visual_Function,Papilledema_FrisenGrade,Papilloedema
grade (Frisén),NR,15,Mean,2.5,SD,0.8,NA,NA,NA,score,Table 1

Markey_2020_BrainCommun,IIHDT,AZD4017,Clinical_Severity,Headache_Days,Headache
days (per 28 days),NR,16,Mean,17.2,SD,8.8,NA,NA,NA,days,Table 1

Markey_2020_BrainCommun,IIHDT,Placebo,Clinical_Severity,Headache_Days,Headache
days (per 28 days),NR,15,Mean,20.1,SD,7.8,NA,NA,NA,days,Table 1

Cello_2016_JNeuroophthalmol,IIHTT,AllArmsCombined,Visual_Function,VisualField_PMD,PMD
(dB) - Study Eye,NR,165,Mean,-3.5,SD,1.5,NA,NA,NA,dB,Table 1

Cello_2016_JNeuroophthalmol,IIHTT,AllArmsCombined,Visual_Function,VisualField_PMD,PMD
(dB) - Fellow Eye,NR,165,Mean,-2.1,SD,1.6,NA,NA,NA,dB,Table 1

Cello_2016_JNeuroophthalmol,IIHTT,AllArmsCombined,Visual_Function,Papilledema_FrisenGrade,Frisen
Grade - Study Eye,NR,165,Mean,2.8,SD,1,NA,NA,NA,score,Table 1

Cello_2016_JNeuroophthalmol,IIHTT,AllArmsCombined,Visual_Function,Papilledema_FrisenGrade,Frisen
Grade - Fellow Eye,NR,165,Mean,2.7,SD,1,NA,NA,NA,score,Table 1

Code snippet

STUDY_ID,PARENT_TRIAL_ID,ROW_TYPE,ARM_ID,ARM_ID_TREATMENT,ARM_ID_COMPARATOR,OUTCOME_DOMAIN,OUTCOME_NAME_STANDARDIZED,OUTCOME_NAME_AS_REPORTED,OUTCOME_DEFINITION_TEXT,TIMEPOINT_AS_REPORTED,TIMEPOINT_DAYS_FROM_BASELINE,DATA_TYPE,BASELINE_MEAN,BASELINE_SD,BASELINE_N,FOLLOWUP_MEAN,FOLLOWUP_SD,FOLLOWUP_N,CHANGE_FROM_BASELINE_MEAN,CHANGE_FROM_BASELINE_SD,N_ANALYZED,EFFECT_MEASURE_TYPE,EFFECT_VALUE,EFFECT_CI_LOWER,EFFECT_CI_UPPER,EFFECT_P_VALUE,ADJUSTED_OR_UNADJUSTED,COVARIATES_ADJUSTED_FOR_TEXT,UNITS_OR_SCALE,OUTCOME_SOURCE_LOCATION

Wall_2014_JAMA,IIHTT,ArmOutcome,ACZ,NA,NA,Visual_Function,VisualField_PMD,Perimetric
mean deviation,Study eye,6
months,NR,Continuous,-3.53,1.49,86,-2.1,1.93,86,1.43,1.92,86,NA,NA,NA,NA,NA,NA,NA,dB,Table
2

Wall_2014_JAMA,IIHTT,ArmOutcome,Placebo,NA,NA,Visual_Function,VisualField_PMD,Perimetric
mean deviation,Study eye,6
months,NR,Continuous,-3.45,1.52,79,-2.74,1.83,79,0.71,1.6,79,NA,NA,NA,NA,NA,NA,NA,dB,Table
2

Wall_2014_JAMA,IIHTT,BetweenArmContrast,NA,ACZ,Placebo,Visual_Function,VisualField_PMD,Perimetric
mean deviation,Study eye,6
months,NR,Continuous,NA,NA,NA,NA,NA,NA,NA,NA,165,MD,0.73,0,1.46,0.05,Adjusted,\"baseline
PMD, center, baseline VFQ-25 score\",dB,Table 2

Wall_2014_JAMA,IIHTT,ArmOutcome,ACZ,NA,NA,Visual_Function,Papilledema_FrisenGrade,Papilledema
grade,Study eye,6
months,NR,Continuous,2.8,1,86,1.5,1.1,86,-1.34,1.03,86,NA,NA,NA,NA,NA,NA,NA,score,Table
2

Wall_2014_JAMA,IIHTT,ArmOutcome,Placebo,NA,NA,Visual_Function,Papilledema_FrisenGrade,Papilledema
grade,Study eye,6
months,NR,Continuous,2.8,1.1,79,2.1,1.1,79,-0.69,0.85,79,NA,NA,NA,NA,NA,NA,score,Table
2

Wall_2014_JAMA,IIHTT,BetweenArmContrast,NA,ACZ,Placebo,Visual_Function,Papilledema_FrisenGrade,Papilledema
grade,Study eye,6
months,NR,Continuous,NA,NA,NA,NA,NA,NA,NA,NA,165,MD,-0.64,-0.95,-0.34,\<0.001,Adjusted,\"baseline
grade, center, baseline VFQ-25 score\",score,Table 2

Wall_2014_JAMA,IIHTT,ArmOutcome,ACZ,NA,NA,Anthropometrics,Weight,Weight,NR,6
months,NR,Continuous,103.7,21.8,86,96.6,22.4,86,-7.08,6.86,86,NA,NA,NA,NA,NA,NA,NA,kg,Table
2

Wall_2014_JAMA,IIHTT,ArmOutcome,Placebo,NA,NA,Anthropometrics,Weight,Weight,NR,6
months,NR,Continuous,101.9,20.4,79,98.6,21,79,-3.2,5.27,79,NA,NA,NA,NA,NA,NA,NA,kg,Table
2

Wall_2014_JAMA,IIHTT,BetweenArmContrast,NA,ACZ,Placebo,Anthropometrics,Weight,Weight,NR,6
months,NR,Continuous,NA,NA,NA,NA,NA,NA,NA,NA,165,MD,-3.88,-5.88,-1.88,0.001,Adjusted,\"baseline
weight, center, baseline VFQ-25 score\",kg,Table 2

Wall_2014_JAMA,IIHTT,ArmOutcome,ACZ,NA,NA,ICP_CSF,CSF_OpeningPressure,CSF
opening pressure,NR,6
months,NR,Continuous,34.3,8.2,86,28.2,8.9,86,-6.1,8.3,86,NA,NA,NA,NA,NA,NA,NA,cmH2O,Table
2

Wall_2014_JAMA,IIHTT,ArmOutcome,Placebo,NA,NA,ICP_CSF,CSF_OpeningPressure,CSF
opening pressure,NR,6
months,NR,Continuous,35.1,9.6,79,30.8,9.7,79,-4.2,9.7,79,NA,NA,NA,NA,NA,NA,NA,cmH2O,Table
2

Wall_2014_JAMA,IIHTT,BetweenArmContrast,NA,ACZ,Placebo,ICP_CSF,CSF_OpeningPressure,CSF
opening pressure,NR,6
months,NR,Continuous,NA,NA,NA,NA,NA,NA,NA,NA,165,MD,-1.9,-4.9,1.1,0.2,Adjusted,\"baseline
pressure, center, baseline VFQ-25 score\",cmH2O,Table 2

Wall_2014_JAMA,IIHTT,ArmOutcome,ACZ,NA,NA,HRQoL,NEI_VFQ25,NEI VFQ-25
composite score,NR,6
months,NR,Continuous,80.1,12.7,86,86.8,11.2,86,6.65,11.77,86,NA,NA,NA,NA,NA,NA,NA,score,Table
2

Wall_2014_JAMA,IIHTT,ArmOutcome,Placebo,NA,NA,HRQoL,NEI_VFQ25,NEI VFQ-25
composite score,NR,6
months,NR,Continuous,80.3,12.7,79,83.9,13.7,79,3.58,11.51,79,NA,NA,NA,NA,NA,NA,NA,score,Table
2

Wall_2014_JAMA,IIHTT,BetweenArmContrast,NA,ACZ,Placebo,HRQoL,NEI_VFQ25,NEI
VFQ-25 composite score,NR,6
months,NR,Continuous,NA,NA,NA,NA,NA,NA,NA,NA,165,MD,3.07,0.1,6.04,0.04,Adjusted,\"baseline
VFQ-25 score, center\",score,Table 2

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ArmOutcome,ACZ,NA,NA,Visual_Function,VisualField_Grade,Visual
field grade (right eye),Median grade,Initial
visit,NR,Ordinal,NR,NR,20,NR,NR,20,NR,NR,20,Median,3,1,3,NA,NA,NA,score,Table
3a

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ArmOutcome,ACZ,NA,NA,Visual_Function,VisualField_Grade,Visual
field grade (right eye),Median grade,Third
month,NR,Ordinal,NR,NR,20,NR,NR,20,NR,NR,20,Median,2.5,1,3,NA,NA,NA,score,Table
3a

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ArmOutcome,ACZ,NA,NA,Visual_Function,VisualField_Grade,Visual
field grade (right eye),Median grade,Sixth
month,NR,Ordinal,NR,NR,20,NR,NR,20,NR,NR,20,Median,2,0,3,NA,NA,NA,score,Table
3a

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ArmOutcome,ACZ,NA,NA,Visual_Function,VisualField_Grade,Visual
field grade (right eye),Median grade,Twelfth
month,NR,Ordinal,NR,NR,20,NR,NR,20,NR,NR,20,Median,1,0,3,NA,NA,NA,score,Table
3a

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ArmOutcome,Topiramate,NA,NA,Visual_Function,VisualField_Grade,Visual
field grade (right eye),Median grade,Initial
visit,NR,Ordinal,NR,NR,20,NR,NR,20,NR,NR,20,Median,3,2,3,NA,NA,NA,score,Table
3a

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ArmOutcome,Topiramate,NA,NA,Visual_Function,VisualField_Grade,Visual
field grade (right eye),Median grade,Third
month,NR,Ordinal,NR,NR,20,NR,NR,20,NR,NR,20,Median,2,1,3,NA,NA,NA,score,Table
3a

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ArmOutcome,Topiramate,NA,NA,Visual_Function,VisualField_Grade,Visual
field grade (right eye),Median grade,Sixth
month,NR,Ordinal,NR,NR,20,NR,NR,20,NR,NR,20,Median,2,1,3,NA,NA,NA,score,Table
3a

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ArmOutcome,Topiramate,NA,NA,Visual_Function,VisualField_Grade,Visual
field grade (right eye),Median grade,Twelfth
month,NR,Ordinal,NR,NR,20,NR,NR,20,NR,NR,20,Median,1,0,3,NA,NA,NA,score,Table
3a

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ArmOutcome,ACZ,NA,NA,Visual_Function,VisualField_Grade,Visual
field grade (left eye),Median grade,Initial
visit,NR,Ordinal,NR,NR,20,NR,NR,20,NR,NR,20,Median,3,1,3,NA,NA,NA,score,Table
3b

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ArmOutcome,ACZ,NA,NA,Visual_Function,VisualField_Grade,Visual
field grade (left eye),Median grade,Third
month,NR,Ordinal,NR,NR,20,NR,NR,20,NR,NR,20,Median,2,1,3,NA,NA,NA,score,Table
3b

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ArmOutcome,ACZ,NA,NA,Visual_Function,VisualField_Grade,Visual
field grade (left eye),Median grade,Sixth
month,NR,Ordinal,NR,NR,20,NR,NR,20,NR,NR,20,Median,2,0,3,NA,NA,NA,score,Table
3b

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ArmOutcome,ACZ,NA,NA,Visual_Function,VisualField_Grade,Visual
field grade (left eye),Median grade,Twelfth
month,NR,Ordinal,NR,NR,20,NR,NR,20,NR,NR,20,Median,1,0,3,NA,NA,NA,score,Table
3b

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ArmOutcome,Topiramate,NA,NA,Visual_Function,VisualField_Grade,Visual
field grade (left eye),Median grade,Initial
visit,NR,Ordinal,NR,NR,20,NR,NR,20,NR,NR,20,Median,3,2,3,NA,NA,NA,score,Table
3b

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ArmOutcome,Topiramate,NA,NA,Visual_Function,VisualField_Grade,Visual
field grade (left eye),Median grade,Third
month,NR,Ordinal,NR,NR,20,NR,NR,20,NR,NR,20,Median,2.5,1,3,NA,NA,NA,score,Table
3b

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ArmOutcome,Topiramate,NA,NA,Visual_Function,VisualField_Grade,Visual
field grade (left eye),Median grade,Sixth
month,NR,Ordinal,NR,NR,20,NR,NR,20,NR,NR,20,Median,2,1,3,NA,NA,NA,score,Table
3b

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ArmOutcome,Topiramate,NA,NA,Visual_Function,VisualField_Grade,Visual
field grade (left eye),Median grade,Twelfth
month,NR,Ordinal,NR,NR,20,NR,NR,20,NR,NR,20,Median,1.5,1,3,NA,NA,NA,score,Table
3b

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,BetweenArmContrast,NA,Topiramate,ACZ,Visual_Function,VisualField_Grade,Visual
field grade (right eye),Comparison of grades,Twelfth
month,NR,Ordinal,NA,NA,NA,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,0.873,Unadjusted,NA,p-value,Table
3a

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,BetweenArmContrast,NA,Topiramate,ACZ,Visual_Function,VisualField_Grade,Visual
field grade (left eye),Comparison of grades,Twelfth
month,NR,Ordinal,NA,NA,NA,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,0.4,Unadjusted,NA,p-value,Table
3b

Celebisoy_2007_ActaNeurolScand,CELEBISOY_TOPIRAMATE_VS_ACZ,ArmOutcome,Topiramate,NA,NA,Anthropometrics,WeightLoss,Weight
loss,Range of weight loss,12
months,NR,Continuous,NR,NR,20,NR,NR,20,NR,NR,20,Mean,9.75,Range,6,28,kg,text
p. 325

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,ArmOutcome,WeightLoss_plus_ACZ,NA,NA,Visual_Function,Papilledema_FrisenGrade_Change,Change
in papilledema
grade,NR,Follow-up,NR,Continuous,NR,NR,28,NR,NR,28,2.8,1.1,28,NA,NA,NA,NA,NA,NA,NA,grade,Table
2

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,ArmOutcome,WeightLoss_Only,NA,NA,Visual_Function,Papilledema_FrisenGrade_Change,Change
in papilledema
grade,NR,Follow-up,NR,Continuous,NR,NR,9,NR,NR,9,2.8,1.3,9,NA,NA,NA,NA,NA,NA,NA,grade,Table
2

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,ArmOutcome,ACZ_Only,NA,NA,Visual_Function,Papilledema_FrisenGrade_Change,Change
in papilledema
grade,NR,Follow-up,NR,Continuous,NR,NR,16,NR,NR,16,0.3,0.5,16,NA,NA,NA,NA,NA,NA,NA,grade,Table
2

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,ArmOutcome,NoTreatment,NA,NA,Visual_Function,Papilledema_FrisenGrade_Change,Change
in papilledema
grade,NR,Follow-up,NR,Continuous,NR,NR,4,NR,NR,4,0,0,4,NA,NA,NA,NA,NA,NA,NA,grade,Table
2

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,ArmOutcome,WeightLoss_plus_ACZ,NA,NA,Anthropometrics,WeightChange_Percent,Change
in weight
(%),NR,Follow-up,NR,Continuous,NR,NR,28,NR,NR,28,-7.4,6.7,28,NA,NA,NA,NA,NA,NA,NA,%,Table
2

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,ArmOutcome,WeightLoss_Only,NA,NA,Anthropometrics,WeightChange_Percent,Change
in weight
(%),NR,Follow-up,NR,Continuous,NR,NR,9,NR,NR,9,-13.7,11,9,NA,NA,NA,NA,NA,NA,NA,%,Table
2

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,ArmOutcome,ACZ_Only,NA,NA,Anthropometrics,WeightChange_Percent,Change
in weight
(%),NR,Follow-up,NR,Continuous,NR,NR,16,NR,NR,16,0.8,4.1,16,NA,NA,NA,NA,NA,NA,NA,%,Table
2

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,ArmOutcome,NoTreatment,NA,NA,Anthropometrics,WeightChange_Percent,Change
in weight
(%),NR,Follow-up,NR,Continuous,NR,NR,4,NR,NR,4,-1.5,1.7,4,NA,NA,NA,NA,NA,NA,NA,%,Table
2

Kupersmith_2016_IOVS,IIHTT,ArmOutcome,ACZ,NA,NA,Biomarker,CSF_Leptin,CSF
Leptin,NR,6
months,NR,Continuous,125.1,67.8,29,114.2,65.8,29,-10.8,25.9,29,NA,NA,NA,NA,NA,NA,NA,ng/mL,Table
1

Kupersmith_2016_IOVS,IIHTT,ArmOutcome,Placebo,NA,NA,Biomarker,CSF_Leptin,CSF
Leptin,NR,6
months,NR,Continuous,124.7,69,28,119.5,70.1,28,-5.2,16.2,28,NA,NA,NA,NA,NA,NA,NA,ng/mL,Table
1

Kupersmith_2016_IOVS,IIHTT,BetweenArmContrast,NA,ACZ,Placebo,Biomarker,CSF_Leptin,CSF
Leptin,NR,6
months,NR,Continuous,NA,NA,NA,NA,NA,NA,NA,NA,57,MD,-5.6,NA,NA,0.51,Unadjusted,NA,ng/mL,Table
1

Kupersmith_2016_IOVS,IIHTT,ArmOutcome,ACZ,NA,NA,Biomarker,CSF_Cortisol,CSF
Cortisol,NR,6
months,NR,Continuous,2.3,1.2,29,1.1,0.6,29,-1.2,1.2,29,NA,NA,NA,NA,NA,NA,NA,μg/dL,Table
1

Kupersmith_2016_IOVS,IIHTT,ArmOutcome,Placebo,NA,NA,Biomarker,CSF_Cortisol,CSF
Cortisol,NR,6
months,NR,Continuous,2.2,0.9,28,1.3,0.7,28,-0.9,1.1,28,NA,NA,NA,NA,NA,NA,NA,μg/dL,Table
1

Kupersmith_2016_IOVS,IIHTT,BetweenArmContrast,NA,ACZ,Placebo,Biomarker,CSF_Cortisol,CSF
Cortisol,NR,6
months,NR,Continuous,NA,NA,NA,NA,NA,NA,NA,NA,57,MD,-0.3,NA,NA,0.34,Unadjusted,NA,μg/dL,Table
1

Wong_2007_BMCOphthalmol,WONG_WEIGHTLOSS_IIH,ArmOutcome,WeightGain,NA,NA,GlobalOutcome,OnTreatment,Patients
on treatment at most recent review,NR,24 months or
more,NR,Dichotomous,NA,NA,12,NA,NA,12,NA,NA,12,CountOnly,8,NA,NA,NA,NA,NA,count,Table
1

Wong_2007_BMCOphthalmol,WONG_WEIGHTLOSS_IIH,ArmOutcome,WeightLoss,NA,NA,GlobalOutcome,OnTreatment,Patients
on treatment at most recent review,NR,24 months or
more,NR,Dichotomous,NA,NA,7,NA,NA,7,NA,NA,7,CountOnly,1,NA,NA,NA,NA,NA,count,Table
1

Wong_2007_BMCOphthalmol,WONG_WEIGHTLOSS_IIH,BetweenArmContrast,NA,WeightLoss,WeightGain,GlobalOutcome,OnTreatment,On
treatment vs Not on treatment,NR,24 months or
more,NR,Dichotomous,NA,NA,NA,NA,NA,NA,NA,NA,19,NA,NA,NA,NA,0.04,Unadjusted,NA,p-value,Table
1

Wong_2007_BMCOphthalmol,WONG_WEIGHTLOSS_IIH,BetweenArmContrast,NA,WeightLoss,WeightGain,GlobalOutcome,Probability_of_continuing_Rx,Probability
of continuing Rx,NR,5
years,NR,TimeToEvent,NA,NA,NA,NA,NA,NA,NA,NA,31,HR,NR,NR,NR,0.04,Unadjusted,NA,p-value,Figure
1

Markey_2020_BrainCommun,IIHDT,ArmOutcome,AZD4017,NA,NA,ICP_CSF,CSF_OpeningPressure,ICP
(cmH2O),NR,12
weeks,NR,Continuous,34.3,7.6,16,28,8.8,16,-6.3,6,16,NA,NA,NA,NA,NA,NA,NA,cmH2O,Table
2

Markey_2020_BrainCommun,IIHDT,ArmOutcome,Placebo,NA,NA,ICP_CSF,CSF_OpeningPressure,ICP
(cmH2O),NR,12
weeks,NR,Continuous,34.4,6.2,15,31.3,9.5,15,-3.2,8.1,15,NA,NA,NA,NA,NA,NA,NA,cmH2O,Table
2

Markey_2020_BrainCommun,IIHDT,BetweenArmContrast,NA,AZD4017,Placebo,ICP_CSF,CSF_OpeningPressure,ICP
(cmH2O),Adjusted mean change,12
weeks,NR,Continuous,NA,NA,NA,NA,NA,NA,NA,NA,31,MD,-3.1,-9.2,3,0.31,Adjusted,baseline
ICP,cmH2O,Table 2

Markey_2020_BrainCommun,IIHDT,ArmOutcome,AZD4017,NA,NA,Anthropometrics,Weight,Weight
(kg),NR,12
weeks,NR,Continuous,102,17.1,16,97.6,16.5,16,-4.4,2.9,16,NA,NA,NA,NA,NA,NA,NA,kg,Table
2

Markey_2020_BrainCommun,IIHDT,ArmOutcome,Placebo,NA,NA,Anthropometrics,Weight,Weight
(kg),NR,12
weeks,NR,Continuous,100,16.1,15,98.1,17.1,15,-1.9,2.8,15,NA,NA,NA,NA,NA,NA,NA,kg,Table
2

Markey_2020_BrainCommun,IIHDT,BetweenArmContrast,NA,AZD4017,Placebo,Anthropometrics,Weight,Weight
(kg),Adjusted mean change,12
weeks,NR,Continuous,NA,NA,NA,NA,NA,NA,NA,NA,31,MD,-2.6,-4.8,-0.3,0.03,Adjusted,baseline
weight,kg,Table 2

Markey_2020_BrainCommun,IIHDT,ArmOutcome,AZD4017,NA,NA,Visual_Function,VisualField_PMD,Perimetric
mean deviation (dB),Worse eye,12
weeks,NR,Continuous,-2,1.2,16,-1.2,1.3,16,0.8,0.7,16,NA,NA,NA,NA,NA,NA,NA,dB,Table
2

Markey_2020_BrainCommun,IIHDT,ArmOutcome,Placebo,NA,NA,Visual_Function,VisualField_PMD,Perimetric
mean deviation (dB),Worse eye,12
weeks,NR,Continuous,-2.1,1.4,15,-1.7,1.8,15,0.4,1.1,15,NA,NA,NA,NA,NA,NA,NA,dB,Table
2

Markey_2020_BrainCommun,IIHDT,BetweenArmContrast,NA,AZD4017,Placebo,Visual_Function,VisualField_PMD,Perimetric
mean deviation (dB),Adjusted mean change,12
weeks,NR,Continuous,NA,NA,NA,NA,NA,NA,NA,NA,31,MD,0.4,-0.4,1.2,0.34,Adjusted,baseline
PMD,dB,Table 2

Markey_2020_BrainCommun,IIHDT,ArmOutcome,AZD4017,NA,NA,Visual_Function,Papilledema_FrisenGrade,Papilloedema
grade (Frisén),NR,12
weeks,NR,Continuous,2.3,0.9,16,1.4,0.9,16,-0.9,0.7,16,NA,NA,NA,NA,NA,NA,NA,score,Table
2

Markey_2020_BrainCommun,IIHDT,ArmOutcome,Placebo,NA,NA,Visual_Function,Papilledema_FrisenGrade,Papilloedema
grade (Frisén),NR,12
weeks,NR,Continuous,2.5,0.8,15,2,1.1,15,-0.5,0.8,15,NA,NA,NA,NA,NA,NA,NA,score,Table
2

Markey_2020_BrainCommun,IIHDT,BetweenArmContrast,NA,AZD4017,Placebo,Visual_Function,Papilledema_FrisenGrade,Papilloedema
grade (Frisén),Adjusted mean change,12
weeks,NR,Continuous,NA,NA,NA,NA,NA,NA,NA,NA,31,MD,-0.3,-0.8,0.2,0.19,Adjusted,baseline
grade,score,Table 2

Markey_2020_BrainCommun,IIHDT,ArmOutcome,AZD4017,NA,NA,Clinical_Severity,Headache_Days,Headache
days (per 28 days),NR,12
weeks,NR,Continuous,17.2,8.8,16,10.6,10.1,16,-6.6,8.7,16,NA,NA,NA,NA,NA,NA,NA,days,Table
2

Markey_2020_BrainCommun,IIHDT,ArmOutcome,Placebo,NA,NA,Clinical_Severity,Headache_Days,Headache
days (per 28 days),NR,12
weeks,NR,Continuous,20.1,7.8,15,18.1,9.4,15,-1.9,8.5,15,NA,NA,NA,NA,NA,NA,NA,days,Table
2

Markey_2020_BrainCommun,IIHDT,BetweenArmContrast,NA,AZD4017,Placebo,Clinical_Severity,Headache_Days,Headache
days (per 28 days),Adjusted mean change,12
weeks,NR,Continuous,NA,NA,NA,NA,NA,NA,NA,NA,31,MD,-4.6,-10,0.8,0.09,Adjusted,baseline
headache days,days,Table 2

Cello_2016_JNeuroophthalmol,IIHTT,ArmOutcome,ACZ,NA,NA,Visual_Function,VisualField_PMD_Improved_gt1dB,PMD
Improved \>= 1 dB (Study Eye),NR,6
months,NR,Dichotomous,NA,NA,86,NA,NA,86,NA,NA,86,CountOnly,47,NA,NA,NA,NA,NA,count,Table
1

Cello_2016_JNeuroophthalmol,IIHTT,ArmOutcome,Placebo,NA,NA,Visual_Function,VisualField_PMD_Improved_gt1dB,PMD
Improved \>= 1 dB (Study Eye),NR,6
months,NR,Dichotomous,NA,NA,79,NA,NA,79,NA,NA,79,CountOnly,31,NA,NA,NA,NA,NA,count,Table
1

Cello_2016_JNeuroophthalmol,IIHTT,BetweenArmContrast,NA,ACZ,Placebo,Visual_Function,VisualField_PMD_Improved_gt1dB,PMD
Improved \>= 1 dB (Study Eye),NR,6
months,NR,Dichotomous,NA,NA,NA,NA,NA,NA,NA,NA,165,OR,1.84,0.96,3.54,0.07,Unadjusted,NA,odds
ratio,Table 1

Cello_2016_JNeuroophthalmol,IIHTT,ArmOutcome,ACZ,NA,NA,Visual_Function,VisualField_PMD_Improved_gt2dB,PMD
Improved \>= 2 dB (Study Eye),NR,6
months,NR,Dichotomous,NA,NA,86,NA,NA,86,NA,NA,86,CountOnly,33,NA,NA,NA,NA,NA,count,Table
1

Cello_2016_JNeuroophthalmol,IIHTT,ArmOutcome,Placebo,NA,NA,Visual_Function,VisualField_PMD_Improved_gt2dB,PMD
Improved \>= 2 dB (Study Eye),NR,6
months,NR,Dichotomous,NA,NA,79,NA,NA,79,NA,NA,79,CountOnly,18,NA,NA,NA,NA,NA,count,Table
1

Cello_2016_JNeuroophthalmol,IIHTT,BetweenArmContrast,NA,ACZ,Placebo,Visual_Function,VisualField_PMD_Improved_gt2dB,PMD
Improved \>= 2 dB (Study Eye),NR,6
months,NR,Dichotomous,NA,NA,NA,NA,NA,NA,NA,NA,165,OR,2.09,1.06,4.12,0.03,Unadjusted,NA,odds
ratio,Table 1

Cello_2016_JNeuroophthalmol,IIHTT,ArmOutcome,ACZ,NA,NA,Visual_Function,VisualField_PMD_Worsened_gt2dB,PMD
Worsened \>= 2 dB (Study Eye),NR,6
months,NR,Dichotomous,NA,NA,86,NA,NA,86,NA,NA,86,CountOnly,5,NA,NA,NA,NA,NA,count,Table
2

Cello_2016_JNeuroophthalmol,IIHTT,ArmOutcome,Placebo,NA,NA,Visual_Function,VisualField_PMD_Worsened_gt2dB,PMD
Worsened \>= 2 dB (Study Eye),NR,6
months,NR,Dichotomous,NA,NA,79,NA,NA,79,NA,NA,79,CountOnly,11,NA,NA,NA,NA,NA,count,Table
2

Cello_2016_JNeuroophthalmol,IIHTT,BetweenArmContrast,NA,ACZ,Placebo,Visual_Function,VisualField_PMD_Worsened_gt2dB,PMD
Worsened \>= 2 dB (Study Eye),NR,6
months,NR,Dichotomous,NA,NA,NA,NA,NA,NA,NA,NA,165,OR,0.39,0.13,1.14,0.08,Unadjusted,NA,odds
ratio,Table 2

Code snippet

STUDY_ID,PARENT_TRIAL_ID,ARM_ID,AE_NAME_STANDARDIZED,AE_NAME_AS_REPORTED,AE_CATEGORY,AE_SEVERITY_CATEGORY,EVENT_COUNT,N_AT_RISK,RELATED_TO_CAI_AS_REPORTED,AE_DEFINITION_TEXT,AE_SOURCE_LOCATION

Wall_2014_JAMA,IIHTT,ACZ,Paresthesia,Paresthesia,Neurologic,AnyGrade,41,86,NR,NR,Table
3

Wall_2014_JAMA,IIHTT,Placebo,Paresthesia,Paresthesia,Neurologic,AnyGrade,8,79,NR,NR,Table
3

Wall_2014_JAMA,IIHTT,ACZ,Dysgeusia,Dysgeusia,Gastrointestinal,AnyGrade,25,86,NR,NR,Table
3

Wall_2014_JAMA,IIHTT,Placebo,Dysgeusia,Dysgeusia,Gastrointestinal,AnyGrade,2,79,NR,NR,Table
3

Wall_2014_JAMA,IIHTT,ACZ,Fatigue,Fatigue,General,AnyGrade,25,86,NR,NR,Table
3

Wall_2014_JAMA,IIHTT,Placebo,Fatigue,Fatigue,General,AnyGrade,18,79,NR,NR,Table
3

Wall_2014_JAMA,IIHTT,ACZ,Nausea,Nausea,Gastrointestinal,AnyGrade,17,86,NR,NR,Table
3

Wall_2014_JAMA,IIHTT,Placebo,Nausea,Nausea,Gastrointestinal,AnyGrade,13,79,NR,NR,Table
3

Wall_2014_JAMA,IIHTT,ACZ,Vomiting,Vomiting,Gastrointestinal,AnyGrade,10,86,NR,NR,Table
3

Wall_2014_JAMA,IIHTT,Placebo,Vomiting,Vomiting,Gastrointestinal,AnyGrade,4,79,NR,NR,Table
3

Wall_2014_JAMA,IIHTT,ACZ,Diarrhea,Diarrhea,Gastrointestinal,AnyGrade,10,86,NR,NR,Table
3

Wall_2014_JAMA,IIHTT,Placebo,Diarrhea,Diarrhea,Gastrointestinal,AnyGrade,5,79,NR,NR,Table
3

Wall_2014_JAMA,IIHTT,ACZ,Tinnitus,Tinnitus,Neurologic,AnyGrade,10,86,NR,NR,Table
3

Wall_2014_JAMA,IIHTT,Placebo,Tinnitus,Tinnitus,Neurologic,AnyGrade,2,79,NR,NR,Table
3

Wall_2014_JAMA,IIHTT,ACZ,MetabolicAcidosis,Decreased carbon
dioxide,Metabolic,AnyGrade,10,86,NR,NR,Table 3

Wall_2014_JAMA,IIHTT,Placebo,MetabolicAcidosis,Decreased carbon
dioxide,Metabolic,AnyGrade,0,79,NR,NR,Table 3

Wall_2This is a systematic data-extraction agent. I cannot provide
hallucinations or information not present in the 74 PDF files.

Code snippet

STUDY_ID,PARENT_TRIAL_ID,MODEL_ID,MODEL_TYPE,MODEL_OUTCOME_NAME_STANDARDIZED,MODEL_OUTCOME_NAME_AS_REPORTED,MODEL_OUTCOME_TYPE,PREDICTOR_NAME_STANDARDIZED,PREDICTOR_NAME_AS_REPORTED,PREDICTOR_CATEGORY,PREDICTOR_CODING_TEXT,EFFECT_MEASURE_TYPE,EFFECT_VALUE,EFFECT_CI_LOWER,EFFECT_CI_UPPER,EFFECT_P_VALUE,ADJUSTED_OR_UNADJUSTED,COVARIATES_ADJUSTED_FOR_TEXT,N_ANALYZED,MODEL_SOURCE_LOCATION

Wall_2014_JAMA,IIHTT,Model1_PMD,Linear,VisualField_PMD,Perimetric mean
deviation,Continuous,Treatment_ACZ_vs_Placebo,Treatment
group,TreatmentAssignment,Acetazolamide vs
Placebo,MD,0.73,0,1.46,0.05,Adjusted,\"baseline PMD, center, and
baseline VFQ-25 score\",165,Table 2

Wall_2014_JAMA,IIHTT,Model2_WeightLoss,Linear,VisualField_PMD,PMD
improvement,Continuous,PercentWeightLoss,% weight loss,WeightChange,per
1% weight loss,Beta,0.07,0.03,0.11,0.001,Adjusted,treatment
group,165,text p. 1648

Wall_2014_JAMA,IIHTT,Model3_Papilledema,Linear,Papilledema_FrisenGrade,Papilledema
grade,Continuous,Treatment_ACZ_vs_Placebo,Treatment
group,TreatmentAssignment,Acetazolamide vs
Placebo,MD,-0.64,-0.95,-0.34,\<0.001,Adjusted,\"baseline papilledema
grade, center, and baseline VFQ-25 score\",165,Table 2

Wall_2014_JAMA,IIHTT,Model4_WeightLoss,Linear,Papilledema_FrisenGrade,Papilledema
grade improvement,Continuous,PercentWeightLoss,% weight
loss,WeightChange,per 1% weight
loss,Beta,0.05,0.03,0.08,0,Adjusted,treatment group,165,text p. 1648

Wall_2014_JAMA,IIHTT,Model5_Weight,Linear,Weight_kg,Weight,Continuous,Treatment_ACZ_vs_Placebo,Treatment
group,TreatmentAssignment,Acetazolamide vs
Placebo,MD,-3.88,-5.88,-1.88,0.001,Adjusted,\"baseline weight, center,
and baseline VFQ-25 score\",165,Table 2

Wall_2014_JAMA,IIHTT,Model6_VFQ25,Linear,HRQoL,NEI VFQ-25 composite
score,Continuous,Treatment_ACZ_vs_Placebo,Treatment
group,TreatmentAssignment,Acetazolamide vs
Placebo,MD,3.07,0.1,6.04,0.04,Adjusted,\"baseline VFQ-25 score and
center\",165,Table 2

Wall_2014_JAMA,IIHTT,Model7_HIT6,Linear,Headache_Disability_HIT6,Headache
Impact Test (HIT-6) score,Continuous,Treatment_ACZ_vs_Placebo,Treatment
group,TreatmentAssignment,Acetazolamide vs
Placebo,MD,-2.19,-4.63,0.24,0.08,Adjusted,\"baseline HIT-6 score and
center\",165,Table 2

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,Model1_Papilledema,Linear,Papilledema_FrisenGrade_Change,Change
in papilledema grade,Continuous,PercentWeightLoss,% weight
loss,WeightChange,per 1% weight
loss,Beta,0.45,NR,NR,\<0.0001,Adjusted,acetazolamide use,57,Table 3

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,Model1_Papilledema,Linear,Papilledema_FrisenGrade_Change,Change
in papilledema grade,Continuous,Treatment_ACZ_vs_None,Acetazolamide
use,TreatmentAssignment,binary: yes vs
no,Beta,0.17,NR,NR,0.48,Adjusted,% weight loss,57,Table 3

Johnson_1998_Ophthalmology,JOHNSON_WEIGHTLOSS_IIH,Model2_Papilledema_6pct,Linear,Papilledema_FrisenGrade_Change,Change
in papilledema grade,Continuous,WeightLoss_gt6pct,Weight loss \>=
6%,WeightChange,binary: yes vs
no,Beta,2.7,NR,NR,\<0.0001,Unadjusted,NA,37,Table 3

Kupersmith_2016_IOVS,IIHTT,Model1_Leptin,Linear,VisualField_PMD_Change,Change
in PMD,Continuous,CSF_Leptin_Change,Change in CSF
leptin,Biomarker,NR,Beta,0.28,NR,NR,0.04,Unadjusted,NA,57,Table 2

Kupersmith_2016_IOVS,IIHTT,Model2_Leptin_Weight,Linear,WeightChange_kg,Change
in weight,Continuous,CSF_Leptin_Change,Change in CSF
leptin,Biomarker,NR,Beta,0.7,NR,NR,\<0.0001,Unadjusted,NA,57,Table 2

Cello_2016_JNeuroophthalmol,IIHTT,Model1_PMD_Improve_gt2dB,Logistic,VisualField_PMD_Improved_gt2dB,\>=2-dB
PMD Improvement (Study
Eye),Dichotomous,Treatment_ACZ_vs_Placebo,Treatment
Group,TreatmentAssignment,Acetazolamide vs
Placebo,OR,2.23,1.12,4.44,0.02,Adjusted,\"Baseline PMD, baseline
papilledema grade\",165,Table 4

Cello_2016_JNeuroophthalmol,IIHTT,Model2_PMD_Improve_gt2dB,Logistic,VisualField_PMD_Improved_gt2dB,\>=2-dB
PMD Improvement (Study Eye),Dichotomous,BaselinePMD,Baseline
PMD,BaselineCovariate,per 1 dB
worse,OR,1.3,1.06,1.6,0.01,Adjusted,\"Treatment group, baseline
papilledema grade\",165,Table 4

Cello_2016_JNeuroophthalmol,IIHTT,Model3_PMD_Improve_gt2dB,Logistic,VisualField_PMD_Improved_gt2dB,\>=2-dB
PMD Improvement (Study
Eye),Dichotomous,BaselinePapilledemaGrade,Baseline papilledema
grade,BaselineCovariate,per 1 grade
worse,OR,1.06,0.76,1.48,0.72,Adjusted,\"Treatment group, baseline
PMD\",165,Table 4

Markey_2020_BrainCommun,IIHDT,Model1_ICP,Linear,CSF_OpeningPressure,ICP
(cmH2O),Continuous,Treatment_AZD4017_vs_Placebo,Treatment,TreatmentAssignment,AZD4017
vs Placebo,MD,-3.1,-9.2,3,0.31,Adjusted,baseline ICP,31,Table 2

Markey_2020_BrainCommun,IIHDT,Model2_Weight,Linear,Weight_kg,Weight
(kg),Continuous,Treatment_AZD4017_vs_Placebo,Treatment,TreatmentAssignment,AZD4017
vs Placebo,MD,-2.6,-4.8,-0.3,0.03,Adjusted,baseline weight,31,Table 2

Markey_2020_BrainCommun,IIHDT,Model3_PMD,Linear,VisualField_PMD,Perimetric
mean deviation
(dB),Continuous,Treatment_AZD4017_vs_Placebo,Treatment,TreatmentAssignment,AZD4017
vs Placebo,MD,0.4,-0.4,1.2,0.34,Adjusted,baseline PMD,31,Table 2

Markey_2020_BrainCommun,IIHDT,Model4_Papilledema,Linear,Papilledema_FrisenGrade,Papilloedema
grade
(Frisén),Continuous,Treatment_AZD4017_vs_Placebo,Treatment,TreatmentAssignment,AZD4017
vs Placebo,MD,-0.3,-0.8,0.2,0.19,Adjusted,baseline grade,31,Table 2

Markey_2020_BrainCommun,IIHDT,Model5_HeadacheDays,Linear,Headache_Days,Headache
days (per 28
days),Continuous,Treatment_AZD4017_vs_Placebo,Treatment,TreatmentAssignment,AZD4017
vs Placebo,MD,-4.6,-10,0.8,0.09,Adjusted,baseline headache days,31,Table
2
